Literature DB >> 1135750

Hemodilution.

K Messmer.   

Abstract

The dilution of whole blood leads to a significant improvement of its rheologic properties based on a decrease in hematocrit and, hence, blood viscosity. Under conditions of normovolemia and an adequate response of the cardiorespiratory system, the acute dilution of blood will enhance the venous return to the heart and thereby improve total and capillary blood flow significantly. In the hematocrit range of 25 to 30 per cent (limited hemodilution), this increase in flow rate is able to compensate fully for the diminished oxygen content of the blood. Changes in oxygen extraction or in oxygenhemoglobin affinity are only encountered at hematocrits below 20 per cent or if hemodilution is associated with hypovolemia. Since normovolemia is the condition sine qua non for the heart to increase its output compensatorily, intentional hemodilution should preferably be performed with colloid solutions which are capable of maintaining the colloid osmotic pressure of plasma and the circulating volume in normal limits. Limited normovolemic hemodilution with its beneficial effects on microcirculatory flow and tissue nutrition is emphasized for the treatment of impaired microcirculation as occurring in shock and low flow states, polycythemia, and high viscosity syndromes. Acute preoperative hemodilution is a means of reducing the use of bank blood and of avoiding the risks of blld transfusions in patients undergoing major elective surgery. Extreme hemodilution and total body washout in hypothermia appear to be effective clinical tools.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1135750     DOI: 10.1016/s0039-6109(16)40641-9

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  34 in total

Review 1.  Autologous blood in obstetrics: where are we going now?

Authors:  Giancarlo Maria Liumbruno; Chiara Liumbruno; Daniela Rafanelli
Journal:  Blood Transfus       Date:  2011-10-25       Impact factor: 3.443

Review 2.  [Normovolemic hemodilution].

Authors:  D J Cŏté
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

Review 3.  Supra-plasma expanders: the future of treating blood loss and anemia without red cell transfusions?

Authors:  Amy G Tsai; Beatriz Y Salazar Vázquez; Axel Hofmann; Seetharama A Acharya; Marcos Intaglietta
Journal:  J Infus Nurs       Date:  2015 May-Jun

Review 4.  An overview of blood-sparing techniques used in spine surgery during the perioperative period.

Authors:  Marek Szpalski; Robert Gunzburg; Bernard Sztern
Journal:  Eur Spine J       Date:  2004-06-15       Impact factor: 3.134

5.  Perioperative Management of a Jehovah's Witness Presenting for Skull Base Surgery.

Authors:  M A Chaney; W S Jellish; J P Leonetti
Journal:  Skull Base Surg       Date:  1996

6.  Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation.

Authors:  Beatriz Y Salazar Vázquez; Reto Wettstein; Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Biochim Biophys Acta       Date:  2008-05-04

7.  Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04       Impact factor: 3.443

8.  The use of blood components in surgical transfusion therapy.

Authors:  C F Högman; L Bagge; L Thorén
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

9.  Effects of exchange transfusion with perfluorochemical emulsions on hepatic oxygen supply and blood flow in the rat.

Authors:  W B Bizot; R D Rink
Journal:  Experientia       Date:  1985-09-15

10.  Effects of pentoxifylline and nitroprusside on guinea pig cochlear blood flow in relationship to various hematocrit values.

Authors:  Y Ohinata; K Makimoto; H Takahashi
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.